Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Differential expression of long non-coding RNAs are related to proliferation and histological diversity in follicular lymphomas.

Roisman A, Castellano G, Navarro A, Gonzalez-Farre B, Pérez-Galan P, Esteve-Codina A, Dabad M, Heath S, Gut M, Bosio M, Bellot P, Salembier P, Oliveras A, Slavutsky I, Magnano L, Horn H, Rosenwald A, Ott G, Aymerich M, López-Guillermo A, Jares P, Martín-Subero JI, Campo E, Hernández L.

Br J Haematol. 2019 Feb;184(3):373-383. doi: 10.1111/bjh.15656. Epub 2018 Nov 22.

PMID:
30565652
2.

Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.

Lee-Vergés E, Hanna BS, Yazdanparast H, Rodríguez V, Rodríguez ML, Giró A, Vidal-Crespo A, Rosich L, Amador V, Aymerich M, Villamor N, Delgado J, Lichter P, Pérez-Galán P, López-Guerra M, Campo E, Seiffert M, Colomer D.

Int J Cancer. 2018 Nov 23. doi: 10.1002/ijc.32010. [Epub ahead of print]

PMID:
30468254
3.

Insulin-like growth factor levels and chronic lymphocytic leukaemia: results from the MCC-Spain and EpiLymph-Spain studies.

Casabonne D, Benavente Y, Costas L, Robles C, Gonzalez-Barca E, de la Banda E, Alonso E, Aymerich M, Campo E, Marcos-Gragera R, Tardón A, Olmedo-Requena R, Gimeno E, Martínez-López A, Casanovas O, Castaño-Vinyals G, Aragonés N, Pollán M, Kogevinas M, de Sanjosé S.

Br J Haematol. 2018 Nov 19. doi: 10.1111/bjh.15583. [Epub ahead of print] No abstract available.

PMID:
30450673
4.

Early T-cell precursor lymphoblastic leukaemia: response to FLAG-IDA and high-dose cytarabine with sorafenib after initial refractoriness.

Bataller A, Garrote M, Oliver-Caldés A, López-Guerra M, Colomer D, Aymerich M, Camós M, Vega-García N, Díaz-Beyá M, Esteve J.

Br J Haematol. 2018 Oct 18. doi: 10.1111/bjh.15601. [Epub ahead of print] No abstract available.

PMID:
30334573
5.

Mutations in RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.

Giménez N, Martínez-Trillos A, Montraveta A, Lopez-Guerra M, Rosich L, Nadeu F, Valero JG, Aymerich M, Magnano L, Rozman M, Matutes E, Delgado J, Bauman T, Gine E, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer AR, Puente XS, López-Otín C, Lopez-Guillermo A, Campo E, Colomer D, Villamor N.

Haematologica. 2018 Sep 27. pii: haematol.2018.196931. doi: 10.3324/haematol.2018.196931. [Epub ahead of print]

6.

Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system.

Aymerich MS, Aso E, Abellanas MA, Tolon RM, Ramos JA, Ferrer I, Romero J, Fernández-Ruiz J.

Biochem Pharmacol. 2018 Nov;157:67-84. doi: 10.1016/j.bcp.2018.08.016. Epub 2018 Aug 17. Review.

PMID:
30121249
7.

Cognitive Therapy for Dementia Patients: A Systematic Review.

Carrion C, Folkvord F, Anastasiadou D, Aymerich M.

Dement Geriatr Cogn Disord. 2018;46(1-2):1-26. doi: 10.1159/000490851. Epub 2018 Aug 9. Review.

8.

Adherence to the Western, Prudent, and Mediterranean dietary patterns and chronic lymphocytic leukemia in the MCC-Spain study.

Solans M, Castelló A, Benavente Y, Marcos-Gragera R, Amiano P, Gracia-Lavedan E, Costas L, Robles C, Gonzalez-Barca E, de la Banda E, Alonso E, Aymerich M, Campo E, Dierssen-Sotos T, Fernández-Tardón G, Olmedo-Requena R, Gimeno E, Castaño-Vinyals G, Aragonés N, Kogevinas M, de Sanjose S, Pollán M, Casabonne D.

Haematologica. 2018 Nov;103(11):1881-1888. doi: 10.3324/haematol.2018.192526. Epub 2018 Jun 28.

9.

The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia.

Rojo-Bustamante E, Abellanas MA, Clavero P, Thiolat ML, Li Q, Luquin MR, Bezard E, Aymerich MS.

Neurobiol Dis. 2018 Oct;118:64-75. doi: 10.1016/j.nbd.2018.06.019. Epub 2018 Jun 21.

PMID:
29936234
10.

Stereological Estimates of Glutamatergic, GABAergic, and Cholinergic Neurons in the Pedunculopontine and Laterodorsal Tegmental Nuclei in the Rat.

Luquin E, Huerta I, Aymerich MS, Mengual E.

Front Neuroanat. 2018 May 11;12:34. doi: 10.3389/fnana.2018.00034. eCollection 2018.

11.

The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia.

Beekman R, Chapaprieta V, Russiñol N, Vilarrasa-Blasi R, Verdaguer-Dot N, Martens JHA, Duran-Ferrer M, Kulis M, Serra F, Javierre BM, Wingett SW, Clot G, Queirós AC, Castellano G, Blanc J, Gut M, Merkel A, Heath S, Vlasova A, Ullrich S, Palumbo E, Enjuanes A, Martín-García D, Beà S, Pinyol M, Aymerich M, Royo R, Puiggros M, Torrents D, Datta A, Lowy E, Kostadima M, Roller M, Clarke L, Flicek P, Agirre X, Prosper F, Baumann T, Delgado J, López-Guillermo A, Fraser P, Yaspo ML, Guigó R, Siebert R, Martí-Renom MA, Puente XS, López-Otín C, Gut I, Stunnenberg HG, Campo E, Martin-Subero JI.

Nat Med. 2018 Jun;24(6):868-880. doi: 10.1038/s41591-018-0028-4. Epub 2018 May 21.

12.

A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.

Clot G, Jares P, Giné E, Navarro A, Royo C, Pinyol M, Martín-Garcia D, Demajo S, Espinet B, Salar A, Ferrer A, Muntañola A, Aymerich M, Rauert-Wunderlich H, Jaffe ES, Connors JM, Gascoyne RD, Delabie J, López-Guillermo A, Ott G, Wright GW, Staudt LM, Rosenwald A, Scott DW, Rimsza LM, Beà S, Campo E.

Blood. 2018 Jul 26;132(4):413-422. doi: 10.1182/blood-2018-03-838136. Epub 2018 May 16.

PMID:
29769262
13.

Expression of the transcribed ultraconserved region 70 and the related long non-coding RNA AC092652.2-202 has prognostic value in Chronic Lymphocytic Leukaemia.

Bomben R, Roisman A, D'Agaro T, Castellano G, Baumann T, Delgado J, López-Guillermo A, Zucchetto A, Dal-Bo M, Bravin V, Slavutsky I, Vlasova A, Guigó R, Martin-Subero JI, Chapaprieta V, Beekman R, Martin-García D, Beà S, Salaverria I, Aymerich M, Campo E, Gattei V, Hernández L.

Br J Haematol. 2018 Apr 24. doi: 10.1111/bjh.15237. [Epub ahead of print] No abstract available.

PMID:
29687884
14.

Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples.

Ugarte A, Corbacho D, Aymerich MS, García-Osta A, Cuadrado-Tejedor M, Oyarzabal J.

Neurotherapeutics. 2018 Jul;15(3):742-750. doi: 10.1007/s13311-018-0624-5.

PMID:
29675823
15.

FDI-Unilever Brush Day & Night partnership: 12 years of improving behaviour for better oral health.

Kell K, Aymerich MA, Horn V.

Int Dent J. 2018 May;68 Suppl 1:3-6. doi: 10.1111/idj.12404. Epub 2018 Mar 24.

PMID:
29573414
16.

Determination of hemodynamic risk for vascular disease in planar artery bifurcations.

Otero-Cacho A, Aymerich M, Flores-Arias MT, Abal M, Álvarez E, Pérez-Muñuzuri V, Muñuzuri AP.

Sci Rep. 2018 Feb 12;8(1):2795. doi: 10.1038/s41598-018-21126-1.

17.

Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia.

Mozas P, Rivas-Delgado A, Baumann T, Villamor N, Ortiz-Maldonado V, Aymerich M, Costa D, Navarro A, Giné E, López-Guillermo A, Montserrat E, Delgado J.

Blood Cancer J. 2018 Jan 16;8(1):10. doi: 10.1038/s41408-017-0044-5. No abstract available.

18.

Established and suggested exposures on CLL/SLL etiology: Results from the CLL-MCC-Spain study.

Benavente Y, Casabonne D, Costas L, Robles C, Alonso E, de la Banda E, Gonzalez-Barca E, Marcos-Gragera R, Llorca J, Tardón A, Monleon JJ, Aymerich M, Campo E, Gimeno-Vázquez E, Castaño-Vinyals G, Aragonés N, Pollán M, Kogevinas M, de Sanjosé S.

Cancer Epidemiol. 2018 Feb;52:106-111. doi: 10.1016/j.canep.2017.12.012. Epub 2018 Jan 4.

PMID:
29289901
19.

The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.

Martínez-Trillos A, Pinyol M, Delgado J, Aymerich M, Rozman M, Baumann T, González-Díaz M, Hernández JM, Alcoceba M, Muntañola A, Terol MJ, Navarro B, Giné E, Jares P, Beà S, Navarro A, Colomer D, Nadeu F, Colado E, Payer AR, García-Cerecedo T, Puente XS, López-Otin C, Campo E, López-Guillermo A, Villamor N.

Leuk Lymphoma. 2018 Oct;59(10):2318-2326. doi: 10.1080/10428194.2017.1397660. Epub 2017 Nov 8.

PMID:
29115891
20.

Do workers' health surveillance examinations fulfill their occupational preventive objective? Analysis of the medical practice of occupational physicians in Catalonia, Spain.

Rodríguez-Jareño MC, Molinero E, de Montserrat J, Vallès A, Aymerich M.

Int J Occup Med Environ Health. 2017 Oct 6;30(6):823-848. doi: 10.13075/ijomeh.1896.00911. Epub 2017 Sep 11.

21.

Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.

Nadeu F, Clot G, Delgado J, Martín-García D, Baumann T, Salaverria I, Beà S, Pinyol M, Jares P, Navarro A, Suárez-Cisneros H, Aymerich M, Rozman M, Villamor N, Colomer D, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer ÁR, Puente XS, López-Otín C, López-Guillermo A, Enjuanes A, Campo E.

Leukemia. 2018 Mar;32(3):645-653. doi: 10.1038/leu.2017.291. Epub 2017 Sep 19.

22.

Is there a role for minimal residual disease monitoring in the management of patients with hairy-cell leukaemia?

Ortiz-Maldonado V, Villamor N, Baumann T, Aymerich M, Magnano L, Mozas P, Rivas-Delgado A, Martínez-Trillos A, Giné E, Campo E, López-Guillermo A, Delgado J.

Br J Haematol. 2018 Oct;183(1):127-129. doi: 10.1111/bjh.14900. Epub 2017 Aug 18. No abstract available.

PMID:
28832940
23.

GPR55: A therapeutic target for Parkinson's disease?

Celorrio M, Rojo-Bustamante E, Fernández-Suárez D, Sáez E, Estella-Hermoso de Mendoza A, Müller CE, Ramírez MJ, Oyarzábal J, Franco R, Aymerich MS.

Neuropharmacology. 2017 Oct;125:319-332. doi: 10.1016/j.neuropharm.2017.08.017. Epub 2017 Aug 12.

PMID:
28807673
24.

Study of Different Sol-Gel Coatings to Enhance the Lifetime of PDMS Devices: Evaluation of Their Biocompatibility.

Aymerich M, Gómez-Varela AI, Álvarez E, Flores-Arias MT.

Materials (Basel). 2016 Aug 25;9(9). pii: E728. doi: 10.3390/ma9090728.

25.

Laser Surface Microstructuring of Biocompatible Materials Using a Microlens Array and the Talbot Effect: Evaluation of the Cell Adhesion.

Aymerich M, Nieto D, Álvarez E, Flores-Arias MT.

Materials (Basel). 2017 Feb 22;10(2). pii: E214. doi: 10.3390/ma10020214.

26.

Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier.

Navarro A, Clot G, Martínez-Trillos A, Pinyol M, Jares P, González-Farré B, Martínez D, Trim N, Fernández V, Villamor N, Colomer D, Costa D, Salaverria I, Martín-Garcia D, Erber W, López C, Jayne S, Siebert R, Dyer MJS, Wiestner A, Wilson WH, Aymerich M, López-Guillermo A, Sánchez À, Campo E, Matutes E, Beà S.

Haematologica. 2017 Sep;102(9):e360-e363. doi: 10.3324/haematol.2016.160374. Epub 2017 May 18. No abstract available.

27.

Laser technique for the fabrication of blood vessels-like models for preclinical studies of pathologies under flow conditions.

Aymerich M, Álvarez E, Bao-Varela C, Moscoso I, González-Juanatey JR, Flores-Arias MT.

Biofabrication. 2017 Jun 7;9(2):025033. doi: 10.1088/1758-5090/aa6c3d.

PMID:
28393759
28.

Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease.

Elgueta D, Aymerich MS, Contreras F, Montoya A, Celorrio M, Rojo-Bustamante E, Riquelme E, González H, Vásquez M, Franco R, Pacheco R.

Neuropharmacology. 2017 Feb;113(Pt A):110-123. doi: 10.1016/j.neuropharm.2016.09.028. Epub 2016 Sep 28.

PMID:
27693549
29.

Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks.

Silveira MM, Arnold JC, Laviolette SR, Hillard CJ, Celorrio M, Aymerich MS, Adams WK.

Neurosci Biobehav Rev. 2017 May;76(Pt B):380-395. doi: 10.1016/j.neubiorev.2016.09.007. Epub 2016 Sep 14. Review.

30.

Night shift work and chronic lymphocytic leukemia in the MCC-Spain case-control study.

Costas L, Benavente Y, Olmedo-Requena R, Casabonne D, Robles C, Gonzalez-Barca EM, de la Banda E, Alonso E, Aymerich M, Tardón A, Marcos-Gragera R, Gimeno-Vázquez E, Gómez-Acebo I, Papantoniou K, Castaño-Vinyals G, Aragonés N, Pollán M, Kogevinas M, de Sanjosé S.

Int J Cancer. 2016 Nov 1;139(9):1994-2000. doi: 10.1002/ijc.30272. Epub 2016 Jul 27.

31.

[Quality and compliance with the regulations of workers'health examinations in relation to their preventive purpose].

Rodríguez-Jareño MC, Molinero E, De Montserrat J, Vallès A, Aymerich M.

Arch Prev Riesgos Labor. 2016 Jul-Sep;19(3):146-65. doi: 10.12961/aprl.2016.19.3.02. Catalan, Spanish.

PMID:
27378501
32.

Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.

Celorrio M, Fernández-Suárez D, Rojo-Bustamante E, Echeverry-Alzate V, Ramírez MJ, Hillard CJ, López-Moreno JA, Maldonado R, Oyarzábal J, Franco R, Aymerich MS.

Brain Behav Immun. 2016 Oct;57:94-105. doi: 10.1016/j.bbi.2016.06.010. Epub 2016 Jun 16.

PMID:
27318096
33.

Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.

López C, Bergmann AK, Paul U, Murga Penas EM, Nagel I, Betts MJ, Johansson P, Ritgen M, Baumann T, Aymerich M, Jayne S, Russell RB, Campo E, Dyer MJ, Dürig J, Siebert R.

Br J Haematol. 2016 Apr;173(2):265-73. doi: 10.1111/bjh.13952. Epub 2016 Feb 25.

PMID:
26917488
34.

The use of clinical practice guidelines in primary care: professional mindlines and control mechanisms.

Gené-Badia J, Gallo P, Caïs J, Sánchez E, Carrion C, Arroyo L, Aymerich M.

Gac Sanit. 2016 Sep-Oct;30(5):345-51. doi: 10.1016/j.gaceta.2016.01.005. Epub 2016 Feb 16.

35.

Clinical impact of MYD88 mutations in chronic lymphocytic leukemia.

Martínez-Trillos A, Navarro A, Aymerich M, Delgado J, López-Guillermo A, Campo E, Villamor N.

Blood. 2016 Mar 24;127(12):1611-3. doi: 10.1182/blood-2015-10-678490. Epub 2016 Feb 4. No abstract available.

36.

Fruit and vegetable intake and vitamin C transporter gene (SLC23A2) polymorphisms in chronic lymphocytic leukaemia.

Casabonne D, Gracia E, Espinosa A, Bustamante M, Benavente Y, Robles C, Costas L, Alonso E, Gonzalez-Barca E, Tardón A, Dierssen-Sotos T, Vázquez EG, Aymerich M, Campo E, Jiménez-Moleón JJ, Marcos-Gragera R, Castaño-Vinyals G, Aragones N, Pollan M, Kogevinas M, Urtiaga C, Amiano P, Moreno V, de Sanjose S.

Eur J Nutr. 2017 Apr;56(3):1123-1133. doi: 10.1007/s00394-016-1162-8. Epub 2016 Feb 2.

PMID:
26838684
37.

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.

Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M, Jares P, Navarro A, Martín-García D, Beà S, Salaverria I, Oldreive C, Aymerich M, Suárez-Cisneros H, Rozman M, Villamor N, Colomer D, López-Guillermo A, González M, Alcoceba M, Terol MJ, Colado E, Puente XS, López-Otín C, Enjuanes A, Campo E.

Blood. 2016 Apr 28;127(17):2122-30. doi: 10.1182/blood-2015-07-659144. Epub 2016 Feb 2.

38.

CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.

Montraveta A, Lee-Vergés E, Roldán J, Jiménez L, Cabezas S, Clot G, Pinyol M, Xargay-Torrent S, Rosich L, Arimany-Nardí C, Aymerich M, Villamor N, López-Guillermo A, Pérez-Galán P, Roué G, Pastor-Anglada M, Campo E, López-Guerra M, Colomer D.

Oncotarget. 2016 Feb 2;7(5):5507-20. doi: 10.18632/oncotarget.6685.

39.

CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.

Baumann T, Delgado J, Santacruz R, Martínez-Trillos A, Rozman M, Aymerich M, López C, Costa D, Carrió A, Villamor N, Montserrat E.

Br J Haematol. 2016 Jan;172(1):48-55. doi: 10.1111/bjh.13788. Epub 2015 Nov 12.

PMID:
26559905
40.

Structures for G-Protein-Coupled Receptor Tetramers in Complex with G Proteins.

Cordomí A, Navarro G, Aymerich MS, Franco R.

Trends Biochem Sci. 2015 Oct;40(10):548-551. doi: 10.1016/j.tibs.2015.07.007.

41.

Laser-based surface multistructuring using optical elements and the Talbot effect.

Aymerich M, Nieto D, Flores-Arias MT.

Opt Express. 2015 Sep 21;23(19):24369-82. doi: 10.1364/OE.23.024369.

PMID:
26406642
42.

Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia.

Salaverria I, Martín-Garcia D, López C, Clot G, García-Aragonés M, Navarro A, Delgado J, Baumann T, Pinyol M, Martin-Guerrero I, Carrió A, Costa D, Queirós AC, Jayne S, Aymerich M, Villamor N, Colomer D, González M, López-Guillermo A, Campo E, Dyer MJ, Siebert R, Armengol L, Beà S.

Genes Chromosomes Cancer. 2015 Nov;54(11):668-80. doi: 10.1002/gcc.22277. Epub 2015 Aug 25.

43.

A laser-based technology for fabricating a soda-lime glass based microfluidic device for circulating tumour cell capture.

Nieto D, Couceiro R, Aymerich M, Lopez-Lopez R, Abal M, Flores-Arias MT.

Colloids Surf B Biointerfaces. 2015 Oct 1;134:363-9. doi: 10.1016/j.colsurfb.2015.07.007. Epub 2015 Jul 11.

PMID:
26218523
44.

Non-coding recurrent mutations in chronic lymphocytic leukaemia.

Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martín-Subero JI, Munar M, Rubio-Pérez C, Jares P, Aymerich M, Baumann T, Beekman R, Belver L, Carrio A, Castellano G, Clot G, Colado E, Colomer D, Costa D, Delgado J, Enjuanes A, Estivill X, Ferrando AA, Gelpí JL, González B, González S, González M, Gut M, Hernández-Rivas JM, López-Guerra M, Martín-García D, Navarro A, Nicolás P, Orozco M, Payer ÁR, Pinyol M, Pisano DG, Puente DA, Queirós AC, Quesada V, Romeo-Casabona CM, Royo C, Royo R, Rozman M, Russiñol N, Salaverría I, Stamatopoulos K, Stunnenberg HG, Tamborero D, Terol MJ, Valencia A, López-Bigas N, Torrents D, Gut I, López-Guillermo A, López-Otín C, Campo E.

Nature. 2015 Oct 22;526(7574):519-24. doi: 10.1038/nature14666. Epub 2015 Jul 22.

PMID:
26200345
45.

The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.

Xargay-Torrent S, López-Guerra M, Rosich L, Montraveta A, Roldán J, Rodríguez V, Villamor N, Aymerich M, Lagisetti C, Webb TR, López-Otín C, Campo E, Colomer D.

Oncotarget. 2015 Sep 8;6(26):22734-49.

46.

Neuroprotective Effect of JZL184 in MPP(+)-Treated SH-SY5Y Cells Through CB2 Receptors.

Aymerich MS, Rojo-Bustamante E, Molina C, Celorrio M, Sánchez-Arias JA, Franco R.

Mol Neurobiol. 2016 May;53(4):2312-9. doi: 10.1007/s12035-015-9213-3. Epub 2015 May 15.

PMID:
25976369
47.

Aberrant Epstein-Barr virus antibody patterns and chronic lymphocytic leukemia in a Spanish multicentric case-control study.

Casabonne D, Benavente Y, Robles C, Costas L, Alonso E, Gonzalez-Barca E, Tardón A, Dierssen-Sotos T, Vázquez EG, Aymerich M, Campo E, Castaño-Vinyals G, Aragones N, Pollan M, Kogevinas M, Juwana H, Middeldorp J, de Sanjose S.

Infect Agent Cancer. 2015 Feb 9;10:5. doi: 10.1186/1750-9378-10-5. eCollection 2015.

48.

Seroreactivity against Merkel cell polyomavirus and other polyomaviruses in chronic lymphocytic leukaemia, the MCC-Spain study.

Robles C, Casabonne D, Benavente Y, Costas L, Gonzalez-Barca E, Aymerich M, Campo E, Tardon A, Jiménez-Moleón JJ, Castaño-Vinyals G, Dierssen-Sotos T, Michel A, Kranz L, Aragonés N, Pollan M, Kogevinas M, Pawlita M, de Sanjose S.

J Gen Virol. 2015 Aug;96(8):2286-92. doi: 10.1099/vir.0.000167. Epub 2015 Apr 28.

PMID:
25920529
49.

How much do workers' health examinations add to health and safety at the workplace? Occupational preventive usefulness of routine health examinations.

Rodríguez-Jareño MC, Molinero E, de Montserrat J, Vallès A, Aymerich M.

Gac Sanit. 2015 Jul-Aug;29(4):266-73. doi: 10.1016/j.gaceta.2014.11.001. Epub 2014 Dec 17.

50.

Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.

Rosich L, Montraveta A, Xargay-Torrent S, López-Guerra M, Roldán J, Aymerich M, Salaverria I, Beà S, Campo E, Pérez-Galán P, Roué G, Colomer D.

Oncotarget. 2014 Aug 30;5(16):6788-800.

Supplemental Content

Loading ...
Support Center